Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.
Morales A, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, Elliott S, Goldenberg L, Gottesman I, Grober ED, Guyatt GH, Holmes DT, Lee JC; Canadian Men’s Health Foundation Multidisciplinary Guidelines Task Force on Testosterone Deficiency. Morales A, et al. Among authors: goldenberg l. CMAJ. 2015 Dec 8;187(18):1369-1377. doi: 10.1503/cmaj.150033. Epub 2015 Oct 26. CMAJ. 2015. PMID: 26504097 Free PMC article. Review. No abstract available.
Prostate specific antigen: an updated review.
So A, Goldenberg L, Gleave ME. So A, et al. Among authors: goldenberg l. Can J Urol. 2003 Dec;10(6):2040-50. Can J Urol. 2003. PMID: 14704108 Review.
Canadian guidelines for the management of benign prostatic hyperplasia.
Nickel JC, Herschorn S, Corcos J, Donnelly B, Drover D, Elhilali M, Goldenberg L, Grantmyre J, Laroche B, Norman R, Piercy B, Psooy K, Steinhoff G, Trachtenberg J, Saad F, Tanguay S; Canadian Prostate Health Council; Canadian Urological Association Guidelines Committee. Nickel JC, et al. Among authors: goldenberg l. Can J Urol. 2005 Jun;12(3):2677-83. Can J Urol. 2005. PMID: 16011814
Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT.
Klotz L, O'Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, Horwitz E, Malone S, Goldenberg L, Gospodarowicz M, Crook JM. Klotz L, et al. Among authors: goldenberg l. J Clin Oncol. 2015 Apr 1;33(10):1151-6. doi: 10.1200/JCO.2014.58.2973. Epub 2015 Mar 2. J Clin Oncol. 2015. PMID: 25732157 Free PMC article. Clinical Trial.
113 results